Anis Hamid

Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer

Anis Hamid, Kathryn P. Gray, Grace Shaw et al. · European Urology · 2018 · 257 citations

Metastatic Prostate Cancer, Urology, Compound Genomic Alterations +6

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

James P Buteau, Andrew Martin, Louise Emmett et al. · The Lancet Oncology · 2022 · 239 citations

Biomarker (Medicine), Prognostic Biomarkers, Urology +7

EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer

Katherine L. Morel, Anjali V. Sheahan, Deborah L. Burkhart et al. · Nature Cancer · 2021 · 228 citations · Full text

Ezh2 Inhibition, Dsrna–sting–interferon Stress, Medicine +6

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet Oncology · 2023 · 172 citations

Urology, Overall Survival, Genitourinary Cancer +8

Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry

Edoardo Francini, Kathryn P. Gray, Grace Shaw et al. · Prostate Cancer and Prostatic Diseases · 2019 · 74 citations · Full text

Urology, Oncology, Surgical Oncology +9